Epitopea is a cancer immunotherapeutic company developing accessible off-the-shelf RNA-based immunotherapies. The company has identified novel aberrantly expressed tumor-specific antigens (aeTSA’s) that are hidden in non-canonical DNA, known as CryptigenTM TSAs, using its proprietary CryptoMapTM platform. These hidden CryptigenTM TSAs were first discovered through research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at the Université de Montréal.

Epitopea is backed by a syndicate of leading life science investors. For additional information, please visit www.epitopea.com and follow us on LinkedIn.